Galactosylceramidase, Novus Biologicals, NBP3-32361

Our team has carried out deep research in the published scientific literature to identify papers and reports using antibodies directed against human galactosylceramidase and followed up by extraction and evaluation of the available data to assess its performance according to pAbmAbs rating criteria.

YCharOS is here conducting a large head-to-head study comparing 6 commercial research antibodies against human galactosylceramidase encoded by GALC gene.

The collection of antibodies was tested using OCUM-1 WT and GALC KD cells in the applications WB (WT and KD cell lysates/30 µg protein), IP (WT cell lysate) and IF (WT and KD cells) according to YCharOS standard protocols (see reference).

In WB (1:1000 Ab dilution) NBP3-32361 detected a band of appr. 60 kDa in both WT and KD cell lysate. A band of appr. 48 kDa was detected following IP (2 µg Ab used). This band was as intense as the corresponding band in input extract (5% of starting material) and in immunodepleted extract (5% of total unbound fraction). A 75 kDa band was not detected in IP. In IF (1:100 Ab dilution), comparable staining intensities were observed in both KO and WT cells.

We highly encourage other scientists to share their observations.